Tag MASH

Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for NASH/MASH.

Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of…